Cellectar Biosciences reports 79.2% major response rate in Phase 2 CLOVER-WaM iopofosine I 131 analysis after BTK inhibitors
Bitget2026/09/29 11:31- Cellectar BioSciences flagged new Phase 2 CLOVER-WaM subset results for iopofosine I 131 in BTK inhibitor-refractory Waldenström macroglobulinemia.
- Findings will be presented Oct. 15, 2026 at the International Workshop for Waldenström Macroglobulinemia in Palm Springs, California.
- The analysis showed strong tumor response with durable benefit in heavily pretreated patients treated immediately following BTK inhibitor therapy.
- Management kept plans to start a Phase 3 confirmatory trial in early 2027.
- The company targets a U.S. accelerated-approval filing in 1H27, citing Breakthrough Therapy Designation and a potential end-2027 decision timeline.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Justin Sun Expects a Drop in Bitcoin — Details of the One-Hour Meeting Have Emerged
From "selling subscriptions" to "selling results": Adobe (ADBE.US) experiments with weekly billing for Acrobat, BTIG says growth sustainability remains to be verified
At the MAX conference held last week, Adobe unveiled new Agentic AI tools and previewed the upcoming local MCP (Model Context Protocol) integration. This feature will allow creators to directly access third-party agents within Photoshop, Illustrator, Premiere, and After Effects.
AI investment boom leads to job growth only at construction sites
Crypto prices
More
